ARA-290 vs LL-37
Both ARA-290 and LL-37 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →LL-37
Evidence BCathelicidin LL-37
The only human cathelicidin antimicrobial peptide. Active against bacteria, viruses, and biofilms. Investigated topically for infected wounds and mucosal infections.
View full LL-37 profile →Side-by-Side
| Attribute | ARA-290 | LL-37 |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy | Not FDA-approved — endogenous antimicrobial peptide; clinical trials for infected wounds |
| Typical Dose | Trial range: 1–4 mg subcutaneous daily | Trial range: topical or intralesional |
| Clinics Indexed | 9 | 19 |
| Categories | anti-inflammatory, neuroprotection | immune, anti-inflammatory |
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Key reported benefits — LL-37
- ✓Broad antimicrobial activity
- ✓Wound healing
- ✓Anti-biofilm
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.